FY26-27 Pediatric Covid-19 Vaccines

The contract awarded by the Centers for Disease Control and Prevention (CDC) involves Indefinite Delivery/Indefinite Quantity (ID/IQ) agreements with manufacturers of pediatric vaccines for the procurement of standard commercial pediatric vaccines. These contracts support the Vaccine for Children (VFC) program, which aims to provide federally funded vaccines to eligible children, including those who are Medicaid-eligible, uninsured, American Indian/Alaska Native, or insured children whose coverage does not include vaccines but receive immunizations at federally qualified health centers or rural health clinics. The program ensures widespread immunization access to promote public health and reduce overall disease burden. This contract specifically addresses the supply of pediatric COVID-19 vaccines for the 2026-2027 season but also includes provisions to purchase vaccines for the 2025-2026 season to maintain continuity before the main supply period begins. Manufacturers eligible to bid must meet the statutory definition, encompassing entities that manufacture, import, process, or distribute pediatric vaccines. The contract allows for the use of VFC funds as well as Section 317 vaccine purchase funds to acquire vaccines at prices below commercial rates. Additionally, awardees may purchase extra quantities for non-federally eligible children using state or local funds. The solicitation was issued by the CDC Office of Acquisition Services under the Department of Health and Human Services, with responses due by mid-March 2026.